Climb Bio (NASDAQ:CLYM) Cut to “Sell” at Wall Street Zen

Posted by Brian Himes on Oct 6th, 2026

Wall Street Zen downgraded shares of Climb Bio (NASDAQ:CLYM – Free Report) from a hold rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other research firms have also recently weighed in on CLYM. Piper Sandler set a $40.00 price target on shares of Climb Bio and gave the company an “overweight” rating in a report on Thursday, September 3rd. Wedbush reissued an “outperform” rating and set a $20.00 target price on shares of Climb Bio in a research report on Wednesday, August 19th. BTIG Research raised their target price on shares of Climb Bio from $20.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. B. Riley Financial reaffirmed a “buy” rating on shares of Climb Bio in a report on Friday, September 4th. Finally, Oppenheimer upped their price target on Climb Bio from $18.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Climb Bio has an average rating of “Buy” and a consensus target price of $27.62.

Read Our Latest Analysis on Climb Bio

Climb Bio Trading Up 1.0%

CLYM opened at $11.05 on Friday. The firm has a market cap of $634.71 million, a price-to-earnings ratio of -13.31 and a beta of -0.04. Climb Bio has a 12 month low of $1.54 and a 12 month high of $18.33. The stock has a fifty day moving average price of $14.09 and a 200-day moving average price of $11.78.

Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. On average, equities research analysts forecast that Climb Bio will post -0.78 EPS for the current year.

Insider Transactions at Climb Bio

In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the completion of the transaction, the director owned 467,969 shares of the company’s stock, valued at approximately $6,397,136.23. This trade represents a 17.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Climb Bio

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Climb Bio in the 2nd quarter worth $30,708,000. Braidwell LP grew its stake in Climb Bio by 102.6% during the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after purchasing an additional 1,569,352 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Climb Bio in the second quarter valued at about $10,727,000. Parkman Healthcare Partners LLC acquired a new position in shares of Climb Bio in the second quarter valued at about $7,348,000. Finally, 683 Capital Management LLC purchased a new position in shares of Climb Bio in the fourth quarter worth about $807,000. 69.76% of the stock is owned by institutional investors and hedge funds.

Climb Bio Company Profile

(Get Free Report)

Climb Bio, Inc is a clinical-stage biotechnology company focused on developing novel therapies for patients with immune-mediated diseases, including autoimmune disorders. The company’s research is centered on addressing underlying drivers of abnormal immune activity and developing treatments intended to provide durable disease control.

Climb Bio’s activities include the discovery, development and clinical evaluation of investigational biologic medicines. Its programs are designed to target pathways involved in B-cell function, autoantibody production and other mechanisms that contribute to autoimmune disease.